Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
As cytotoxic agents, DTX and PTX have a narrow therapeutic window. BSA dosing leads to great
inter-individual PK variability, which is a major contributor for severe toxicity, especially
in East-Asian populations. DTX exposures measured by area under plasma concentration-time
curve (AUC), PTX exposures measured by the time above a plasma concentration of 0.05 µmol/L
(TC>0.05), are the most biologic effects associated PK parameters for DTX and PTX,
respectively, which could positively predict related toxicities such as neutropenia,
peripheral neuropathy, etc. So, we conducted a randomized clinical trial to compare the
effect on related toxicities and efficacy of PK-guided dosing strategy and BSA dosing
strategy.